HeyJaredScience Fight Club
Your hub for science activism! Stay up to date on news, action, policy, and the fight to take back our science. Hosted by Stand Up for Science.
- Indexed issues, last 90 days
- 12
- Latest publication
- Sep 30, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 4, 2026
Latest issues
We Are Still Unserious About the Climate: Reflections from New York Climate Week (opens the original)
Read excerpt
TL;DR: THE WORLD IS LITERALLY BURNING AND FLOODING AT A CATASTROPHIC RATE WHILE WE FLY ON JETS FROM ALL OVER THE WORLD TO CONVENE IN A GIANT CITY TO HOLD HAPPY HOURS AND HAND OUT GOODY BAGS AND HOST PANELS TO TALK TO EACH OTHER ABOUT HOW THE WORLD IS LITERALLY BURNING AND FLOODING. Read more
Why does therapeutic drug development take so long? Cholesterol and cardiovascular disease: Statins (part 5) (opens the original)
Read excerpt
The first four examples of therapeutics whose development we explored all involved cancer treatment. But the leading killer in the United States is heart disease and the most widely prescribed drugs help reduce the risk of heart disease and other cardiovascular ailments. Here, we explore the most important class of these drugs, the statins. Approximately a quarter of American adults take a statin, the common name for 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Read more
Why does therapeutic drug development take so long? Harnessing the immune system to treat cancer: Cancer immunotherapy (part 4) (opens the original)
Read excerpt
This is the last of four case histories related to cancer treatments. Since well before I first started in science, there were discussions about the role of the immune system in combating cancer. The belief, then with limited experimental evidence, was that we all develop abnormal cells starting on paths on the way to cancer all the time but that our immune systems recognize and remove these. Studies of basic immunology, starting in the 1990s, discovered hints of a new immune system regulatory p
Your colleagues are losing their freedoms. What will you do while you still have yours? (opens the original)
Read excerpt
We need to talk. Read more
Why does therapeutic drug development take so long? Antibodies as drugs: Herceptin (part 3) (opens the original)
Read excerpt
Last week I highlighted Gleevec, one of the first medicines specifically targeted to known genetic changes in certain types of cancer. Gleevec was more or less universally successful in chronic myelogenous leukemia in large part because all of the cancers of this type have essentially the same genetic change. In contrast, most other cancer types are quite heterogeneous with different subtypes of cancer in different individuals. Remarkably, one aspect of this heterogeneity provided a key insight
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.